APOE and Amyloid Disclosure
Educational Handouts from the Generation Study*
Pre-Testing (Decision Tools)
About APOE Genetic Testing
This slide deck PDF above explains background information about APOE genotypes as they relate to dementia risk.
About Amyloid PET Scans
This slide deck was used as part of the Generation Program which studied the medications CNP520 and CAD106.
APOE Gene Test Results & Risk Information
*The e2 form of APOE is rare, so there is not as much data, but based on the available data, the e2 form is associated with a reduced risk of dementia or MCI.
*Because the e2 form is also involved in this gene result, this form of APOE is also rare, and based on the data available, the risk of dementia or MCI is slightly lower or higher than 10 - 15%.
*The e2 form of APEO is rare, but the e3r form is rarer, so we do not have any data available, and the risk of dementia or MCI is unknown.
*This e3 form is the most common form of APOE, and the risk of dementia or MCI is about 10 - 15% meaning that the risk of NOT developing dementia or MCI is 85 - 90%.
*Because the e3r form of APOE is so rare, there is no estimation of the risk of dementia or MCI, but based on evidence, it suggests that the risk may be similar to someone with the e3/e3 form.
*Since e2 is a rare form of APOE, we do not have data available, but the risk of dementia or MCI may be slightly lower or higher than someone with the e3/e3 form.
*With this form of APOE which is not as rare, the risk of developing dementia or MCI is about 20 - 25% meaning that the risk of NOT developing dementia or MCI is 75 - 80%.
*This form of APOE is not as rare, and the risk of developing dementia or MCI is about 30 - 55% meaning that the risk of NOT developing dementia or MCI is 45 - 70%.
Amyloid PET Scan Test Results & Risk Information
This PDF summarizes the brain amyloid test information and results provided as part of Generation Study 2 of the Generation Program.
*We do not know if the risks are similar for all racial and ethnic groups.
Citation: Langlois CM, Bradbury A, Wood EM, Roberts JS, Kim SYH, Riviere ME, Liu F, Reiman EM, Tariot PN, Karlawish J, Langbaum JB. Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimer's Dement (N Y). 2019 Nov 6;5:705-716. doi: 10.1016/j.trci.2019.09.013.
Funding Source: The Generation Program was funded by Novartis and Amgen, in collaboration with the Banner Alzheimer's Institute. Generation Study 1 was supported by funding from the National Institute on Aging (1UF1AG046150), part of the National Institutes of Health, as well as the Alzheimer's Association, FBRI, GHR Foundation and Banner Alzheimer's Foundation.